Delivery Order SPE2DB22D2206-SPE2DB24FHA99
- Not listed
- This federal contract award, valued at $28,471.12, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product, with a completion date of January 8, 2024. This is a firm fixed price delivery order contract, with no set-aside designation. Amerisourcebergen Drug Corp is an established prime contractor providing a wide range of pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of REVLIMID 25 MG CAPSULE 21S. The contract has a firm fixed price ceiling value of $37,445.14 and an ultimate completion date of December 12, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $178,310.12 firm fixed-price delivery order is for the supply of REVLIMID 10 MG CAPSULE 100S, a prescription medication. The contract has an ultimate completion date of December 24, 2024 and was awarded on December 3, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $49,926.80 firm fixed-price delivery order is for the supply of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of April 3, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is a firm fixed price delivery order for the supply of REVLIMID 10 MG Capsules. The award has a ceiling value of $105,612.88 and an ultimate completion date of May 3, 2024. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office Division. The $69,990.84 firm fixed price delivery order is for the procurement of REVLIMID 10 MG CAPSULE 28S, a prescription medication. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. Under this IDC, Amerisourcebergen provides...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,722.57 firm-fixed-price delivery order is for the supply of REVLIMID 25 MG CAPSULE 21S, a specialty pharmaceutical product. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office division, a major pharmaceutical distributor. The $18,722.57 Firm Fixed Price contract is for the delivery of 4565833098 REVLIMID 25 MG CAPSULE 21S, a specialty oncology medication, with a completion date of October 7, 2024. The award is not associated with any set-aside program. AmerisourceBergen holds significant Indefinite Delivery Contracts (IDCs) with the DLA...
- This federal contract award is a delivery order with a ceiling value of $24,963.40 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product, with a period of performance through November 2024. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition....
- This federal contract award, valued at $24,963.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of REVLIMID 2.5 MG CAPSULE 28S, a pharmaceutical product. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB24FHA99Delivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office Division. The $46,660.58 firm fixed-price delivery order is for the supply of REVLIMID 2.5 MG CAPSULE 28S, a prescription medication. The contract has an ultimate completion date of May 29, 2024. Amerisourcebergen is a major pharmaceutical distributor that supplies a wide range of drugs and medical supplies to various U.S. government agencies, particularly the Department of Defense (DoD) and Department of Veterans Affairs (VA). This award is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for Amerisourcebergen to deliver pharmaceutical products and medical supplies to DLA facilities supporting the DoD worldwide. The contract does not have a set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.7k | 5/7/24 |